Bristol-Myers Squibb (BRM) Price & Analysis
BRM Stock Chart & Stats
- Day’s Range
- EUR 55.45 - EUR 57.00
- 52-Week Range
- EUR 39.05 - EUR 61.19
- Previous Close
- EUR 54.26
- Volume
- 7
- Average Volume (3M)
- 1,258
- Market Cap
- EUR 113.97B
- Enterprise Value
- EUR 160.34B
- Total Cash (Recent Filing)
- EUR 12.58B
- Total Debt (Recent Filing)
- EUR 42.88B
- Price to Earnings (P/E)
- 13.8
- Beta
- 0.38
- Next Earnings
- Feb 04, 2027
- EPS Estimate
- 1.36
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.92%
Bulls Say, Bears Say
Bulls Say
Diversified Growth Portfolio
A broad set of commercially meaningful medicines reduces reliance on any single product and supports more durable revenue expansion. The portfolio’s double-digit growth and multiple billion-dollar contributors provide a stronger base for absorbing individual product declines while funding continued innovation.
Pipeline And Product Expansion
Recent approvals and positive late-stage results strengthen the pathway for portfolio renewal beyond existing franchises. Multiple therapeutic areas and development programs provide several potential sources of future growth, helping offset mature-product pressure if execution and regulatory progress continue.
Strong Cash Generation And Efficiency
Substantial liquidity and quarterly operating cash generation give BMS capacity to support research, manufacturing investment, business development, and shareholder commitments. The planned productivity initiative adds a further structural support by targeting $2 billion of efficiencies by the end of 2027.
Bears Say
Eliquis Exclusivity Loss
Eliquis is a major franchise, so the expected post-exclusivity decline creates a material revenue gap that the newer portfolio must replace. Even with continued U.S. growth, this transition can pressure earnings visibility and increase dependence on successful launches and pipeline execution.
Elevated Leverage
The elevated debt burden can constrain capital allocation as BMS manages product investment, business development, dividends, and upcoming franchise transitions. Higher leverage also leaves less flexibility to absorb weaker earnings or fund opportunities if operating performance becomes more volatile.
Clinical Program And Launch Execution Risk
The Zolacel pause delays potential pipeline contribution and introduces meaningful safety and regulatory uncertainty around an otherwise promising autoimmune platform. Restart requirements and authority review could consume resources, extend timelines, and reduce the near-term contribution expected from this program.
Bristol-Myers Squibb News
BRM FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
What is Bristol-Myers Squibb’s market cap?
When is Bristol-Myers Squibb’s upcoming earnings report date?
How were Bristol-Myers Squibb’s earnings last quarter?
Is Bristol-Myers Squibb overvalued?
Does Bristol-Myers Squibb pay dividends?
What is Bristol-Myers Squibb’s EPS estimate?
How many shares outstanding does Bristol-Myers Squibb have?
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
What is the TipRanks Smart Score and how is it calculated?
Bristol-Myers Squibb Stock Smart Score
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher Boerner
- Employees
- 32,500
- Website
- www.bms.com
- Address
- Route 206 & Province Line Road, Princeton, NJ, 08543, US
Bristol-Myers Squibb (BRM) Earnings & Revenues
BRM Company Deck
BRM Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Management reported 7% total revenue growth, 12% growth in the growth portfolio, strong performance from multiple key brands, raised full-year guidance, substantial cash generation, and several positive late-stage pipeline readouts. The principal challenges were the upcoming Eliquis loss of exclusivity, declines in parts of the legacy portfolio and Opdivo, execution issues for Cobenfy, uncertainty around the higher admilparant dose, and the Zolacel program pause following a fatal event. Highlights significantly outweighed the lowlights.
View all DE:BRM earnings summariesBRM Net sales Breakdown
- 54.80% Growth Portfolio
- 45.20% Legacy Portfolio
BRM Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 5 | 3 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 12 | 0 | 0 |